Merck Sharp + Dohme Corp.

Cangming Yang

Barbara A Pio

Michael W Miller

Emma R Parmee

Dong Xiao

Jinlong Jiang

Ronald M Kim

Harry R Chobanian

Yan Guo

Christopher W Plummer

Qiang Tan

Ashley Rouse Lins

Alexander Pasternak

Hubert B Josien

Dong-Ming Shen

Jeffrey John Hale

Zhicai Wu

Haifeng Tang

Fa-Xiang Ding

Duane E DeMong

Zhi-Cai Shi

Xin Gu

Shuzhi Dong

Jiang Chang

Thomas A Bara

Zhiyong Hu

Rui Zhang

Dipshikha Biswas

Min Shu

Michael Miller

Thomas Bara

Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated by the G-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia.

Antidiabetic compounds

Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated by the G-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia. 

Antidiabetic bicyclic compounds

The present invention provides compounds of Formula I and the pharmaceutically acceptable salts thereof, which are inhibitors of the ROMK (Kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure and chronic kidney disease and conditions associated with excessive salt and water retention.

Inhibitors of the renal outer medullary potassium channel

Compounds of structural formula I are inhibitors of prolylcarboxypeptidase (PrCP). The compounds of the present invention are useful for the prevention and treatment of conditions related to the enzymatic activity of PrCP such as abnormal metabolism, including obesity; diabetes; metabolic syndrome; obesity related disorders; and diabetes related disorders. 

Prolylcarboxypeptidase inhibitors

Glucagon receptor antagonist compounds are disclosed. The compounds are useful for treating type 2 diabetes and related conditions. Pharmaceutical compositions and methods of treatment are also included.

Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use

Growing community of inventors

South River, NJ, United States of America

Cangming Yang